We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-15.04%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$185M
AUM Growth
-$43.2M
Cap. Flow
+$19.8M
Cap. Flow %
10.73%
Top 10 Hldgs %
66.67%
Holding
76
New
13
Increased
20
Reduced
16
Closed
22

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$9.46M
2
ZGNX
Zogenix, Inc.
ZGNX
+$5.9M
3
RCM
R1 RCM Inc. Common Stock
RCM
+$5.74M
4
AERI
Aerie Pharmaceuticals
AERI
+$5.26M
5
AMRN
Amarin Corp
AMRN
+$4.88M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$7.55M
2
SAGE
Sage Therapeutics
SAGE
+$4.05M
3
ABT icon
Abbott
ABT
+$3.07M
4
MDT icon
Medtronic
MDT
+$2.65M
5
ANAB icon
AnaptysBio
ANAB
+$2.25M

Sector Composition

Rank Sector Weight
1 Healthcare 87.02%
2 Industrials 10.11%
3 Miscellaneous 2.35%
4 Real Estate 0.52%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPNT
51
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$201K 0.11%
+13,901
New +$227K
NGNE icon
52
Neurogene
NGNE
$732M
$159K 0.09%
+3,686
New +$180K
EPZM
53
DELISTED
Epizyme, Inc
EPZM
$157K 0.08%
25,449
-22,000
-46% -$168K
CFMS
54
DELISTED
Conformis, Inc. Common Stock
CFMS
$49K 0.03%
5,474
+400
+8% +$6.73K
ANAB icon
55
AnaptysBio
ANAB
$1.67B
– –
-22,524
Closed -$2.25M
DVAX
56
DELISTED
Dynavax Technologies
DVAX
– –
-27,000
Closed -$335K
IMUX icon
57
PUT
Immunic
IMUX
$210M
– –
-96
Closed -$10.5K
IOVA icon
58
Iovance Biotherapeutics
IOVA
$3.63B
– –
-44,140
Closed -$497K
KIDS icon
59
OrthoPediatrics
KIDS
$617M
– –
-19,600
Closed -$718K
MDGL icon
60
Madrigal Pharmaceuticals
MDGL
$12.3B
– –
-9,400
Closed -$2.01M
MDT icon
61
Medtronic
MDT
$117B
– –
-26,800
Closed -$2.65M
PODD icon
62
Insulet
PODD
$10.1B
– –
-8,765
Closed -$929K
SGMO
63
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-40,000
Closed -$678K
SPY icon
64
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
– –
-90,000
Closed -$26.2M
VKTX icon
65
Viking Therapeutics
VKTX
$3.75B
– –
-25,000
Closed -$436K
XRAY icon
66
Dentsply Sirona
XRAY
$2.22B
– –
-16,680
Closed -$631K
MODN
67
DELISTED
MODEL N, INC.
MODN
– –
-72,283
Closed -$1.15M
SPPI
68
CALL
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-40,000
Closed -$672K
SPPI
69
PUT
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-60,000
Closed -$1.01M
ISEE
70
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-149,100
Closed -$352K
AGTC
71
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-14,500
Closed -$106K
WMGI
72
DELISTED
Wright Medical Group Inc
WMGI
– –
-66,600
Closed -$1.93M
FOMX
73
PUT
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-25,000
Closed -$143K
DERM
74
DELISTED
Dermira, Inc.
DERM
– –
-40,018
Closed -$436K
MLNT
75
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
– –
-5,296
Closed -$105K
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2018 Portfolio in Review

As of Q4 2018, Eversept Partners held 76 positions worth $185M, down 19% from $228M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Eversept Partners deployed $19.8M of net new capital in Q4 2018, opening 13 new positions and adding to 20 existing holdings. Its largest new stake was Fate Therapeutics: 165,000 shares worth $2.12M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 79% a quarter earlier, followed by Industrials and Miscellaneous.

On the sell side, the largest reduction was Merck, an estimated $7.55M trimmed.

  • Eversept Partners's largest Q4 2018 buy was Fate Therapeutics: 165,000 shares worth $2.12M.
  • Eversept Partners added most to GSK in Q4 2018, an estimated $9.46M increase.
  • Eversept Partners's biggest Q4 2018 reduction was Merck, cutting an estimated $7.55M.
  • Eversept Partners fully exited Medtronic in Q4 2018, selling an estimated $2.65M.
  • Eversept Partners's ten largest holdings make up 67% of its $185M portfolio in Q4 2018.
  • Eversept Partners opened 13 new positions and closed 22 in Q4 2018.
  • Eversept Partners's portfolio value fell 19% quarter-over-quarter to $185M.

Based on Eversept Partners's 13F filing for Q4 2018, filed 13 Feb 2019.